Hassan Rahimi
YOU?
Author Swipe
View article: Silent Struggles: Age-Specific Patterns of Suicidal Ideation and Protective Factors in Kermanshah
Silent Struggles: Age-Specific Patterns of Suicidal Ideation and Protective Factors in Kermanshah Open
Background: Suicide remains a pressing public health concern across the lifespan. While younger adults frequently become the focus of prevention efforts, older adults — particularly in culturally conservative contexts like Kermanshah, Iran…
View article: Immunogenicity and adverse effects of pneumococcal vaccines co-administered with influenza or SARS-CoV-2 vaccines in adults: A systematic review and Meta-analysis
Immunogenicity and adverse effects of pneumococcal vaccines co-administered with influenza or SARS-CoV-2 vaccines in adults: A systematic review and Meta-analysis Open
In adults, co-administration of pneumococcal vaccines with influenza or SARS-CoV-2 vaccines is non-inferior to single-administration; however, it can increase mild-moderate systemic AEs. Data is scarce, and further studies are needed on im…
View article: Targeting FGFRs by pemigatinib induces G1 phase cell cycle arrest, cellular stress and upregulation of tumor suppressor microRNAs
Targeting FGFRs by pemigatinib induces G1 phase cell cycle arrest, cellular stress and upregulation of tumor suppressor microRNAs Open
View article: Targeting FGFRs by pemigatinib induces G1 phase cell cycle arrest, cellular stress and upregulation of tumor suppressor miRNAs
Targeting FGFRs by pemigatinib induces G1 phase cell cycle arrest, cellular stress and upregulation of tumor suppressor miRNAs Open
Background: Fibroblast growth factor receptor (FGFR) gene family alterations are found in several cancers, indicating their importance as potential therapeutic targets. The FGFR-tyrosine kinase inhibitor (TKI) pemigatinib (Pemazyre ® , INC…
View article: Circulating CD137+ T Cell Levels Are Correlated with Response to Pembrolizumab Treatment in Advanced Head and Neck Cancer Patients
Circulating CD137+ T Cell Levels Are Correlated with Response to Pembrolizumab Treatment in Advanced Head and Neck Cancer Patients Open
Pembrolizumab, an anti-PD-1 antibody, has been approved as first-line treatment for recurrent or metastatic head and neck squamous cell carcinoma ((R/M) HNSCC). However, only a minority of patients benefit from immunotherapy, which highlig…
View article: Data from Microvesicle Cargo of Tumor-Associated MUC1 to Dendritic Cells Allows Cross-presentation and Specific Carbohydrate Processing
Data from Microvesicle Cargo of Tumor-Associated MUC1 to Dendritic Cells Allows Cross-presentation and Specific Carbohydrate Processing Open
Tumor-associated glycoproteins are a group of antigens with high immunogenic interest: The glycoforms generated by the aberrant glycosylation are tumor-specific and the novel glycoepitopes exposed can be targets of tumor-specific immune re…
View article: Data from Microvesicle Cargo of Tumor-Associated MUC1 to Dendritic Cells Allows Cross-presentation and Specific Carbohydrate Processing
Data from Microvesicle Cargo of Tumor-Associated MUC1 to Dendritic Cells Allows Cross-presentation and Specific Carbohydrate Processing Open
Tumor-associated glycoproteins are a group of antigens with high immunogenic interest: The glycoforms generated by the aberrant glycosylation are tumor-specific and the novel glycoepitopes exposed can be targets of tumor-specific immune re…
View article: Supplemental Figure 2: Characterization of MUC1-DG75 transfectant cell line and of the MUC1-DG75-MVs. from Microvesicle Cargo of Tumor-Associated MUC1 to Dendritic Cells Allows Cross-presentation and Specific Carbohydrate Processing
Supplemental Figure 2: Characterization of MUC1-DG75 transfectant cell line and of the MUC1-DG75-MVs. from Microvesicle Cargo of Tumor-Associated MUC1 to Dendritic Cells Allows Cross-presentation and Specific Carbohydrate Processing Open
A, MUC1 glycoform expression of MUC1-DG75 transfectant detected by flow cytometry employing anti-MUC1 glycoform specific MoAbs. Only the ST-MUC1 glycoform, (MoAb MYE12), is expressed on the surface of transfectant cells. B, MUC1 distributi…
View article: Supplemental Figure 1: HLAII-DR molecule accumulates at the periphery of DCs after 12 hours incubation from Microvesicle Cargo of Tumor-Associated MUC1 to Dendritic Cells Allows Cross-presentation and Specific Carbohydrate Processing
Supplemental Figure 1: HLAII-DR molecule accumulates at the periphery of DCs after 12 hours incubation from Microvesicle Cargo of Tumor-Associated MUC1 to Dendritic Cells Allows Cross-presentation and Specific Carbohydrate Processing Open
Cellular distribution of HLAII-DR molecules in iDCs was visualized after 2 or 12 hours from cell harvesting and incubation at 37{degree sign}C (columns 1 and 2, respectively) by immunofluorescence staining by Apotome module employing the a…
View article: Figure S3 from TK Inhibitor Pazopanib Primes DCs by Downregulation of the β-Catenin Pathway
Figure S3 from TK Inhibitor Pazopanib Primes DCs by Downregulation of the β-Catenin Pathway Open
Modulation of DCs phenotype during Pazopanib treatment (T0, T1, T2). HLA-DR, CD40 and PD-L1expression is shown for iDCs. mDCs have a strong down-regulation of PD-L1 during pazopanib treatment. Results are representative of Patient 1
View article: Table S1 from TK Inhibitor Pazopanib Primes DCs by Downregulation of the β-Catenin Pathway
Table S1 from TK Inhibitor Pazopanib Primes DCs by Downregulation of the β-Catenin Pathway Open
MoAbs used in this study
View article: Supplemental Figure 1: HLAII-DR molecule accumulates at the periphery of DCs after 12 hours incubation from Microvesicle Cargo of Tumor-Associated MUC1 to Dendritic Cells Allows Cross-presentation and Specific Carbohydrate Processing
Supplemental Figure 1: HLAII-DR molecule accumulates at the periphery of DCs after 12 hours incubation from Microvesicle Cargo of Tumor-Associated MUC1 to Dendritic Cells Allows Cross-presentation and Specific Carbohydrate Processing Open
Cellular distribution of HLAII-DR molecules in iDCs was visualized after 2 or 12 hours from cell harvesting and incubation at 37{degree sign}C (columns 1 and 2, respectively) by immunofluorescence staining by Apotome module employing the a…
View article: Supplementary Figure 2 - PDF file - 3056K from Microvesicle Cargo of Tumor-Associated MUC1 to Dendritic Cells Allows Cross-presentation and Specific Carbohydrate Processing
Supplementary Figure 2 - PDF file - 3056K from Microvesicle Cargo of Tumor-Associated MUC1 to Dendritic Cells Allows Cross-presentation and Specific Carbohydrate Processing Open
A, MUC1 glycoform expression of MUC1-DG75 transfectant detected by flow cytometry employing anti-MUC1 glycoform specific MoAbs. Only the ST-MUC1 glycoform, (MoAb MYE12), is expressed on the surface of transfectant cells. B, MUC1 distributi…
View article: Supplementary Figure 2 - PDF file - 3056K from Microvesicle Cargo of Tumor-Associated MUC1 to Dendritic Cells Allows Cross-presentation and Specific Carbohydrate Processing
Supplementary Figure 2 - PDF file - 3056K from Microvesicle Cargo of Tumor-Associated MUC1 to Dendritic Cells Allows Cross-presentation and Specific Carbohydrate Processing Open
A, MUC1 glycoform expression of MUC1-DG75 transfectant detected by flow cytometry employing anti-MUC1 glycoform specific MoAbs. Only the ST-MUC1 glycoform, (MoAb MYE12), is expressed on the surface of transfectant cells. B, MUC1 distributi…
View article: Table S1 from TK Inhibitor Pazopanib Primes DCs by Downregulation of the β-Catenin Pathway
Table S1 from TK Inhibitor Pazopanib Primes DCs by Downregulation of the β-Catenin Pathway Open
MoAbs used in this study
View article: Data from TK Inhibitor Pazopanib Primes DCs by Downregulation of the β-Catenin Pathway
Data from TK Inhibitor Pazopanib Primes DCs by Downregulation of the β-Catenin Pathway Open
Tyrosine kinase inhibitors (TKIs) target angiogenesis by affecting, for example, the VEGF receptors in tumors and have improved outcomes for patients with metastatic renal cell carcinoma (mRCC). Immune checkpoint inhibitors (ICIs) have als…
View article: Supplementary Figure 1 - PDF file - 42K from Microvesicle Cargo of Tumor-Associated MUC1 to Dendritic Cells Allows Cross-presentation and Specific Carbohydrate Processing
Supplementary Figure 1 - PDF file - 42K from Microvesicle Cargo of Tumor-Associated MUC1 to Dendritic Cells Allows Cross-presentation and Specific Carbohydrate Processing Open
Cellular distribution of HLAII-DR molecules in iDCs was visualized after 2 or 12 hours from cell harvesting and incubation at 37{degree sign}C (columns 1 and 2, respectively) by immunofluorescence staining by Apotome module employing the a…
View article: Figure S3 from TK Inhibitor Pazopanib Primes DCs by Downregulation of the β-Catenin Pathway
Figure S3 from TK Inhibitor Pazopanib Primes DCs by Downregulation of the β-Catenin Pathway Open
Modulation of DCs phenotype during Pazopanib treatment (T0, T1, T2). HLA-DR, CD40 and PD-L1expression is shown for iDCs. mDCs have a strong down-regulation of PD-L1 during pazopanib treatment. Results are representative of Patient 1
View article: Supplementary Figure 1 - PDF file - 42K from Microvesicle Cargo of Tumor-Associated MUC1 to Dendritic Cells Allows Cross-presentation and Specific Carbohydrate Processing
Supplementary Figure 1 - PDF file - 42K from Microvesicle Cargo of Tumor-Associated MUC1 to Dendritic Cells Allows Cross-presentation and Specific Carbohydrate Processing Open
Cellular distribution of HLAII-DR molecules in iDCs was visualized after 2 or 12 hours from cell harvesting and incubation at 37{degree sign}C (columns 1 and 2, respectively) by immunofluorescence staining by Apotome module employing the a…
View article: Figure S1 from TK Inhibitor Pazopanib Primes DCs by Downregulation of the β-Catenin Pathway
Figure S1 from TK Inhibitor Pazopanib Primes DCs by Downregulation of the β-Catenin Pathway Open
A)VEGFR-1 expression on untreated DCs and DCs differentiated with sunitinib and pazopanib B) Fold-increase of the amount of IL- 12/IL-10 and CXCL-10/IL-10 released by untreated DCs and DCs differenziated with sunitinib and pazopanib
View article: Supplemental Figure 2: Characterization of MUC1-DG75 transfectant cell line and of the MUC1-DG75-MVs. from Microvesicle Cargo of Tumor-Associated MUC1 to Dendritic Cells Allows Cross-presentation and Specific Carbohydrate Processing
Supplemental Figure 2: Characterization of MUC1-DG75 transfectant cell line and of the MUC1-DG75-MVs. from Microvesicle Cargo of Tumor-Associated MUC1 to Dendritic Cells Allows Cross-presentation and Specific Carbohydrate Processing Open
A, MUC1 glycoform expression of MUC1-DG75 transfectant detected by flow cytometry employing anti-MUC1 glycoform specific MoAbs. Only the ST-MUC1 glycoform, (MoAb MYE12), is expressed on the surface of transfectant cells. B, MUC1 distributi…
View article: Figure S2 from TK Inhibitor Pazopanib Primes DCs by Downregulation of the β-Catenin Pathway
Figure S2 from TK Inhibitor Pazopanib Primes DCs by Downregulation of the β-Catenin Pathway Open
A) T cell analysis cultured up to 24 hours with pazopanib and sunitinib. B)VEGF-R1 expression on T cells
View article: Data from TK Inhibitor Pazopanib Primes DCs by Downregulation of the β-Catenin Pathway
Data from TK Inhibitor Pazopanib Primes DCs by Downregulation of the β-Catenin Pathway Open
Tyrosine kinase inhibitors (TKIs) target angiogenesis by affecting, for example, the VEGF receptors in tumors and have improved outcomes for patients with metastatic renal cell carcinoma (mRCC). Immune checkpoint inhibitors (ICIs) have als…
View article: Figure S2 from TK Inhibitor Pazopanib Primes DCs by Downregulation of the β-Catenin Pathway
Figure S2 from TK Inhibitor Pazopanib Primes DCs by Downregulation of the β-Catenin Pathway Open
A) T cell analysis cultured up to 24 hours with pazopanib and sunitinib. B)VEGF-R1 expression on T cells
View article: Figure S1 from TK Inhibitor Pazopanib Primes DCs by Downregulation of the β-Catenin Pathway
Figure S1 from TK Inhibitor Pazopanib Primes DCs by Downregulation of the β-Catenin Pathway Open
A)VEGFR-1 expression on untreated DCs and DCs differentiated with sunitinib and pazopanib B) Fold-increase of the amount of IL- 12/IL-10 and CXCL-10/IL-10 released by untreated DCs and DCs differenziated with sunitinib and pazopanib
View article: Proteomic characterization of extracellular vesicles released by third stage larvae of the zoonotic parasite Anisakis pegreffii (Nematoda: Anisakidae)
Proteomic characterization of extracellular vesicles released by third stage larvae of the zoonotic parasite Anisakis pegreffii (Nematoda: Anisakidae) Open
Introduction Anisakis pegreffii is a sibling species within the A. simplex (s.l.) complex requiring marine homeothermic (mainly cetaceans) and heterothermic (crustaceans, fish, and cephalopods) organisms to complete its life cycle. It is a…
View article: Soluble PD-L1 as a Prognostic Factor for Immunotherapy Treatment in Solid Tumors: Systematic Review and Meta-Analysis
Soluble PD-L1 as a Prognostic Factor for Immunotherapy Treatment in Solid Tumors: Systematic Review and Meta-Analysis Open
Blocking the Programmed Cell Death Protein 1 (PD-1)/programmed death ligand-1 (PD-L1) axis has demonstrated great efficacy in cancer immunotherapy treatment and remains the central modality of immune targeting. To support the rational and …
View article: Glycan-Lectin Interactions as Novel Immunosuppression Drivers in Glioblastoma
Glycan-Lectin Interactions as Novel Immunosuppression Drivers in Glioblastoma Open
Despite diagnostic and therapeutic improvements, glioblastoma (GB) remains one of the most threatening brain tumor in adults, underlining the urgent need of new therapeutic targets. Lectins are glycan-binding proteins that regulate several…
View article: Constructing a novel competing Endogenous RNAs network based on NR3C1 and X-linked inhibitor of apoptosis protein genes reveals potential prognostic biomarkers in colorectal cancer
Constructing a novel competing Endogenous RNAs network based on NR3C1 and X-linked inhibitor of apoptosis protein genes reveals potential prognostic biomarkers in colorectal cancer Open
Background: Long noncoding RNAs (lncRNAs) have been recognized as the main modulatory molecules in various cancers and perform as competing endogenous RNAs (ceRNAs). The nuclear hormone receptor superfamily of ligand-activated transcriptio…
View article: Polymeric Nanoparticles Decorated with Monoclonal Antibodies: A New Immobilization Strategy for Increasing Lipase Activity
Polymeric Nanoparticles Decorated with Monoclonal Antibodies: A New Immobilization Strategy for Increasing Lipase Activity Open
Recent advances in nanotechnology techniques enable the production of polymeric nanoparticles with specific morphologies and dimensions and, by tailoring their surfaces, one can manipulate their characteristics to suit specific application…